Skip to main content
Premium Trial:

Request an Annual Quote

ExonHit Therapeutics, Biacore

Premium
ExonHit Therapeutics this week launched its Human GW SpliceArray, a genome-wide splice variant detection tool that monitors more than 23,000 human genes covering 130,000 expressed transcripts and uses over 6 million probes to help study the human proteome.
 
ExonHit said the chip is built on the Affymetrix platform, and offers researchers the ability to interrogate both exons and splice junctions on a single microarray.
 

 
Biacore, a GE Healthcare company, this week launched its Biacore X100 system for label-free protein interaction analysis. The platform uses surface plasmon resonance imaging to determine binding selectivity, kinetics, and affinity using the firm’s suite of sensor chips.
 
Biacore said the automated Biacore X100 is designed for use in busy, multi-project R&D labs, and can provide users with binding information to facilitate protein functionality research.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.